Program
plinabulin
Also written as “Plinabulin”, “Docetaxel + Plinabulin (DP)” and “NPI-2358 + docetaxel”.
Its studies are mostly in Neutropenia · Carcinoma, Non-Small-Cell Lung · Neoplasms · Lymphoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BeyondSpring Pharmaceuticals | 62 open or running | phase 3since Jul 16, 2015 | Jul 16, 2015 | Jun 1, 2029phase 3 · NCT07361484 |
| Nereus Pharmaceuticals | 20 open or running | phase 2since Feb 26, 2008 | May 4, 2006 | none ahead |
Also a collaborator on its studies: covance and icon-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 4, 2006First study: phase 1 study in NeoplasmsNew to Nereus PharmaceuticalsNereus Pharmaceuticals · NCT00322608 · 35 enrolled · United States
- Feb 26, 2008Phase 2 study in NeoplasmsNereus Pharmaceuticals · NCT00630110 · 172 enrolled · United States, Argentina, Australia and more
- Jul 16, 2015BeyondSpring Pharmaceuticals's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to BeyondSpring PharmaceuticalsBeyondSpring Pharmaceuticals · NCT02504489 · 559 enrolled · United States, Australia, China
- Mar 6, 2017Phase 3 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT03102606 · 105 enrolled · United States, China, Russian Federation and more
- Sep 22, 2017Phase 3 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT03294577 · 221 enrolled · China, Ukraine
- Jan 10, 2020Phase 2 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT04227990 · 115 enrolled · China, Ukraine
- Mar 31, 2020Phase 2 study in Chemotherapy-induced NeutropeniaBeyondSpring Pharmaceuticals · NCT04345900 · 55 enrolled · United States, China, Russian Federation and more
- Jan 19, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungBeyondSpring Pharmaceuticals · NCT07361484 · 442 planned
Ahead
- Jun 1, 2029Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungBeyondSpring Pharmaceuticals · NCT07361484
TargetBeta
“Tubulin inhibitor”ChEMBL 37, by rule
Other programs on the same 15 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Paclitaxelrule | Hoffmann-La Roche | phase 4 | 202 |
| Docetaxelrule | Sanofi | phase 4 | 199 |
| cabazitaxelrule | Sanofi | phase 4 | 21 |
| Vinblastinerule | Takeda | phase 4 | 4 |
| desoxyepothilone Brule | beijing-biostar-pharmaceuticals-co-ltd | phase 3 | 19 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07361484Carcinoma, Non-Small-Cell Lung | 3 | Not yet recruiting | BeyondSpring Pharmaceuticals | Jun 1, 2029 | 442 |
| NCT04345900Chemotherapy-induced Neutropenia · United States, China, Russian Federation and more | 2 | Completed | BeyondSpring Pharmaceuticals | Mar 20, 2018 | 55 |
| NCT04227990Chemotherapy-induced Neutropenia · China, Ukraine | 2 | Completed | BeyondSpring Pharmaceuticals | Oct 15, 2018 | 115 |
| NCT03294577Chemotherapy-induced Neutropenia · China, Ukraine | 3 | Active, not recruiting | BeyondSpring Pharmaceuticals | Sep 25, 2020 | 221 |
| NCT03102606Chemotherapy-induced Neutropenia · United States, China, Russian Federation and more | 3 | Completed | BeyondSpring Pharmaceuticals | Dec 12, 2018 | 105 |
| NCT02504489Carcinoma, Non-Small-Cell Lung · United States, Australia, China | 3 | Completed | BeyondSpring Pharmaceuticals | Jul 21, 2021 | 559 |
| NCT00630110Neoplasms · United States, Argentina, Australia and more | 2 | Completed | Nereus Pharmaceuticals | Jun 2011 | 172 |
| NCT00322608Neoplasms · United States | 1 | Completed | Nereus Pharmaceuticals | Sep 2009 | 35 |
How it is read
Names in the registry
- “Plinabulin”, 5 entries
- “Docetaxel + Plinabulin (DP)”, 1 entry
- “NPI-2358 + docetaxel”, 1 entry
- “NPI-2358”, 1 entry
Conditions, from the studies’ own filings
- Neutropenia, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Neoplasms, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.